WO2007148551A1 - Composition orale liquide contenant de l'isopropylméthylphénol - Google Patents

Composition orale liquide contenant de l'isopropylméthylphénol Download PDF

Info

Publication number
WO2007148551A1
WO2007148551A1 PCT/JP2007/061701 JP2007061701W WO2007148551A1 WO 2007148551 A1 WO2007148551 A1 WO 2007148551A1 JP 2007061701 W JP2007061701 W JP 2007061701W WO 2007148551 A1 WO2007148551 A1 WO 2007148551A1
Authority
WO
WIPO (PCT)
Prior art keywords
sodium
liquid oral
oral composition
composition
polyoxyethylene
Prior art date
Application number
PCT/JP2007/061701
Other languages
English (en)
Japanese (ja)
Inventor
Yasuo Nomura
Kazuo Mukasa
Original Assignee
Lion Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lion Corporation filed Critical Lion Corporation
Priority to JP2008522389A priority Critical patent/JP5136797B2/ja
Priority to KR1020087028642A priority patent/KR101380508B1/ko
Publication of WO2007148551A1 publication Critical patent/WO2007148551A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34—Alcohols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34—Alcohols
    • A61K8/347—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/39—Derivatives containing from 2 to 10 oxyalkylene groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/46—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur
    • A61K8/463—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur containing sulfuric acid derivatives, e.g. sodium lauryl sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
    • A61K8/86—Polyethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses

Definitions

  • the present invention exhibits a high penetrating and bactericidal effect on periodontopathic biofilms, has good appearance stability over time during storage at low and high temperatures, and is used in the oral cavity after use and after use.
  • the present invention relates to a liquid oral composition containing isopropylmethylphenol, characterized by being substantially free of ethanol with low irritation and low irritation. Background art
  • Plaque control that is, effective means for prevention and improvement of oral diseases, It is said that it is useful to keep the oral bacteria count at a low level.
  • nonionic germicides such as isopropylmethylphenol have characteristics that tend to have a broader antibacterial spectrum than cationic germicides. It is blended into products and marketed.
  • these nonionic fungicides are oil-soluble compounds and are almost insoluble in water as they are, so they are solubilized by blending various surfactants and solvents such as ethanol.
  • surfactant since the surfactant inactivates the active site of the bactericidal agent, sufficient bactericidal power is not expressed when the blending amount increases, and the blending amount of the surfactant for improving the bactericidal power. If the amount is reduced, the liquid becomes clouded with time at low and high temperatures, and the appearance stability of the composition is impaired.
  • Isopropylmethylphenol is a nonionic fungicide that is attracting attention as a bactericidal preparation with a high penetration bactericidal effect on periodontopathic biofilms.
  • isopropylmethylphenol has been solubilized with low-concentration polyoxyethylene hydrogenated castor oil in the technology for preventing oral disease using isopropinolemethylphenol (Japanese Patent Laid-Open No. 62-24010, JP-A-1-305021, JP-A-7-48237, JP-A-10-330230: refer to Patent Documents 1 to 4), and these compositions all contain ethanol and thus have a high irritation potential. there were.
  • a high-concentration wetting agent is blended so that the water content in the preparation is 40% or less (see JP-A-11-322554: Patent Document 5), or the moisture content is less than half of the blended amount of polyols. It has been proposed to ensure the aging stability and bactericidal activity of isopropylinomethylphenol by adjusting and blending (see JP 2001-199854 A: Patent Document 6). However, these techniques have the disadvantage that the water content is low and the composition has a high viscosity and is not suitable for mouthwashing, or the stickiness in the oral cavity after use is extremely poor.
  • Patent Document 1 Japanese Patent Laid-Open No. 62-24010
  • Patent Document 2 JP-A-1 305021
  • Patent Document 3 Japanese Patent Laid-Open No. 7-48237
  • Patent Document 4 JP-A-10-330230
  • Patent Document 5 Japanese Patent Laid-Open No. 11 322554
  • Patent Document 6 Japanese Unexamined Patent Publication No. 2001-199854
  • the present invention has been made in view of the above circumstances, exhibits a high penetrating and bactericidal effect on periodontopathic biofilms, has good appearance stability over time during storage at low and high temperatures, and is used. It is an object of the present invention to provide a liquid oral composition containing isopropylenomethylphenol and containing substantially no ethanol, which has a low irritation with low stickiness in the oral cavity after use.
  • At least one anionic surfactant selected from the group consisting of polyoxyethylene hydrogenated castor oil with an average addition mole number of ethylene oxide of 40 to 100 moles and an average addition mole number of ethylene oxide of 16 to 18 Is blended with at least one nonionic surfactant selected from 10 to 40 mol of polyoxyethylene alkyl ether, and further selected from glycerin, propylene glycol, butylene glycol, and polyethylene glycol having an average molecular weight of 190 to 630.
  • At least one wetting agent is used in combination with 5 to 15% by weight of the total composition.
  • the composition containing substantially no ethanol in the periodontal pathogenic biofilm is formulated by combining the specific components described above.
  • Excellent bactericidal activity against oral bacteria such as periodontal disease bacteria, excellent appearance stability over time during storage at low and high temperatures, and low stickiness in the mouth during and after mouthwashing It has been found that a high-quality liquid composition for oral cavity can be obtained which has a feeling of use and is excellent in preventing and improving oral diseases.
  • At least one wetting agent selected from glycerin, propylene glycol, butylene glycol, and polyethylene glycol having an average molecular weight of 190 to 630 is 5 to 15% by mass of the total composition
  • liquid oral composition characterized by having a water content in the composition of 70% by mass or more and substantially not containing ethanol.
  • Component (A) is at least one selected from sodium alkyl sulfate having a carbon chain length of 12 to 14 and sodium N-acyl sarcosine, and component (B) has an average added mole number of ethylene oxide. 60 to 100 moles of polyoxyethylene hydrogenated castor oil and a polyoxyethylene alkyl ether power having an alkyl chain with a carbon chain length of 16 to 18 and an average added mole number of ethylene oxide of 20 to 40 moles are selected.
  • the liquid oral composition according to [I] which is at least one kind
  • the liquid oral composition of the present invention exhibits an osmotic and bactericidal effect on periodontopathic biofilms and has good appearance stability over time during storage at low and high temperatures. It is hypoallergenic with low stickiness.
  • the liquid oral composition of the present invention contains isopropylmethylphenol as a bactericidal component, and (A) sodium alkyl sulfate and N-a as an anionic surfactant.
  • the anionic surfactant of component (A) used in the present invention includes sodium alkyl sulfate, N_acyl sarcosine sodium, from the viewpoint of osmotic bactericidal activity against periodontopathic biofilm, taste and irritation.
  • sodium lauryl sulfate and sodium lauryl sarcosine are preferably used.
  • the total amount of component (A) is preferably from 0.05 to 1.0% of the total composition in terms of penetrating bactericidal activity against periodontal pathogenic biofilms and solubilizing isopropylmethylphenol. % By mass, the same shall apply hereinafter), and more preferably 0.05 to 0.5%. If the blending amount is less than 0.05%, it may become cloudy and the appearance stability at high temperature may be impaired.If it exceeds 1.0%, it may precipitate over time during storage at low temperature, cause irritation, and taste may deteriorate. It may get worse.
  • the average number of calories of ethylene oxide with respect to periodontopathic biofilm and the number of calories with an average of ethylene oxide 3 ⁇ 40 ⁇ Use at least one selected from 100 mol polyoxyethylene hydrogenated castor oil and polyoxyethylene alkyl ether having an alkyl chain with a carbon chain length of 16 to 18 and an average added mole number of ethylene oxide of 10 to 40 mol To do.
  • polyoxyethylene alkyl ethers those having an average added mole number of 10 to 40 moles, such as point power of stimulation, are used.
  • polyoxyethylene hydrogenated castor oil with an average number of caromoles of ethylene oxide of 60 to 100 mol and carbon chain length in terms of osmotic bactericidal power against periodontopathic biofilm and solubilization of isopropylmethylphenol.
  • Polyoxyethylene alkyl ethers having an alkyl chain of 16 to 18 and an average addition mole number of ethylene oxide of 20 to 40 mol are preferably used.
  • polyoxyethylene hydrogenated castor oil having an average addition mole number of ethylene oxide of 60 to 100 mol is particularly preferably used.
  • the average number of moles of ethylene oxide added to polyoxyethylene hydrogenated castor oil is less than 40 moles, it will precipitate during storage at low temperatures, Those that exceed are generally not on the market.
  • the average number of added moles of polyoxyethylene alkyl ether is less than 10 moles, those which are precipitated during low-temperature storage as described above and are strongly irritating more than 40 moles are generally not commercially available.
  • the alkyl chain length is less than 16
  • the bitterness and irritation are more than 18 and the appearance stability at low or high temperature is inferior.
  • the total amount of component (B) is preferably from 0.1 to 1.0 in the entire composition in terms of osmotic bactericidal activity against periodontal pathogenic biofilm and solubilization of isopropylmethylphenol. %, More preferably 0.2 to 0.7%. If the blending amount is less than 0.1%, it may be difficult to maintain appearance stability at low and high temperatures, and if it exceeds 1.0%, the bactericidal activity may be impaired. When polyoxyethylene alkyl ether is used as component (B), irritation may occur if the compounding amount exceeds 1.0%.
  • component (C) used in the present invention at least one selected from glycerin, propylene glycol, butylene glycol, and polyethylene glycol having an average molecular weight of 190 to 630 is used.
  • the above-mentioned average molecular weight indicates the average molecular weight described in Cosmetic Raw Material Standards (2nd edition comment), and polyethylene glycol having an average molecular weight of 190 to 630 is polyethylene glycol 200 (average molecular weight 190 to 210).
  • Polyethylene glycol 300 average molecular weight 280 to 320
  • polyethylene glycol 400 average molecular weight 380 to 420
  • polyethylene glycol 600 average molecular weight 570 to 630.
  • component (C) it is preferable to use two or more kinds of component (C) from the viewpoint of appearance stability at low temperature and taste at the time of use. It is preferable to use three or more kinds from the viewpoint of appearance stability at higher temperature. More preferred. Preferred combinations of the two are glycerin and propylene glycol, glycerin and butylene glycol, and glycerin and polyethylene glycol (especially polyethylene glycol # 400). As the three combinations, a combination of glycerin, propylene glycol and polyethylene glycol, or a combination of glycerin, propylene glycol and butylene glycol is preferred.
  • the total blending amount of component (C) is 5 to 15% of the total composition, in terms of appearance stability at low and high temperatures, and stickiness in the oral cavity after use during use. 6 to: 13% is preferable. If the blending amount is less than 5%, it may become cloudy, which makes it difficult to maintain appearance stability at high and low temperatures. If it exceeds 15%, an anionic surfactant may precipitate during storage at low temperatures, or stickiness after use may occur during use.
  • component (C) when blending glycerin, 0.5% or more of the whole composition, and when blending propylene glycol, blend 1% or more of butylene glycol with the whole composition. In this case, it is preferable that 1% or more of the whole composition and polyethylene glycol having an average molecular weight of 190 to 630 are blended by 1% or more of the whole composition.
  • the amount of isopropylmethylphenol used in the present invention is 0.01 to 0.1% of the total composition, particularly 0.02 in terms of exerting the osmotic bactericidal effect of the periodontopathic biofilm. -0.08% power S is preferable. If the blending amount is less than 0.01%, the biofilm may not be sterilized. If it exceeds 0.1%, white turbidity and appearance stability may be reduced. It may be damaged.
  • the water content is preferably 70% or more of the total amount of the composition from the viewpoint of usability and taste, and more preferably 80% or more from the viewpoint of the feeling of use.
  • the upper limit of the amount of water is preferably such that the sum of the lower component amounts of components (A) to (C) and isopropylmethylphenol is 100%, ie 94.84%.
  • (D) triclosan can be blended in the liquid oral composition of the present invention for the purpose of improving the bactericidal power against airborne bacteria.
  • the blending amount should be 0 ⁇ 01-0.1% of the total composition, especially 0.02 to 0.08%. S is preferable. If the blending amount is less than 0.01%, The sterilizing power may not be exhibited, and if it exceeds 0.1%, it may become cloudy and the appearance stability may be impaired.
  • the liquid oral composition of the present invention is substantially free of ethanol.
  • “substantially free of ethanol” means that the amount of ethanol in the composition is preferably lOOppm or less, more preferably 50ppm or less, particularly preferably lOppm or less with respect to the whole composition. The lower limit is Oppm.
  • the liquid oral composition of the present invention is an ethanol derived from a raw material in a fragrance compounded in a power composition containing no ethanol. Therefore, in consideration of these reasons, ethanol is not included in addition to ethanol contained in trace amounts in perfumes.
  • the liquid oral composition of the present invention can be prepared and applied as a mouthwash, liquid dentifrice, etc., but the liquid oral composition of the present invention has a dosage form other than the above components.
  • Appropriate optional components can be blended depending on the situation, for example, wetting agents other than the above components, thickeners, pH adjusters, preservatives, sweeteners, fragrances, surfactants, active ingredients, coloring agents, etc. Can be contained.
  • the wetting agent other than the component (C) described above sorbitol, ethylene glycol, xylite, maltite, lactit and the like can be contained.
  • the blending amount of the moistening agent other than these components (C) is preferably 0 to 6% based on the entire composition.
  • xanthan gum sodium alginate, polybulal alcohol, hydroxychetyl cellulose, carrageenan, sodium carboxymethyl cellulose and the like can be used as long as the effects of the present invention are not hindered.
  • pH adjusters include phthalic acid, phosphoric acid, citrate, succinic acid, acetic acid, fumaric acid, malic acid and carbonic acid and their potassium, sodium and ammonium salts, ribonucleic acid and its salts, and water. At least one kind such as sodium oxide can be used, and in particular, a combination of phosphoric acid and citrate and their sodium salts is preferable.
  • the liquid oral composition of the present invention preferably has sodium dihydrogen phosphate and sodium monohydrogen phosphate as pH adjusting agents, preferably adjusting the pH at 25 ° C. to 5.5 ⁇ 7.5.
  • sodium benzoate, methylparaben, ethylparaben, propylparaben, butylparaben, cetylpyridinium hydrochloride, alkyldiaminoethyldaricin hydrochloride, potassium sorbate and the like can be contained.
  • saccharin sodium As the sweetening agent, saccharin sodium, stepiosite, sucralose, reduced palatinose, erythritol and the like can be contained.
  • fragrance peppermint oil, spearmint oil, eucalyptus oil, winter green oil, clove oil, thyme oil, sage oil, cardamom oil, rosemary oil, marjoram oil, lemon oil, nutmeg oil, lavender oil, paracres Natural essential oils such as oil, and 1_carvone, 1,8—cineole, methyl salicylate, eugenol, thymol, linalool, limonene, Perfume ingredients contained in the above-mentioned natural essential oils such as n-tone, menthyl acetate, citral, camphor, borneol, pinene, spirantol, etc.
  • surfactants other than the above components (A) and (B) include anions such as lauroylmethyl taurine, isyl amino acid salt, sodium dodecylbenzenesulfonate, sodium ⁇ -sulfo fatty acid alkyl ester, alkyl phosphate ester salt, etc.
  • amphoteric surfactants such as alkyl dimethylamino amino acid betaine and fatty acid amidopropyldimethylamino amino acid betaine, ⁇ fatty acid acyl ⁇ ⁇ ⁇ ⁇ carboxymethyl ⁇ hydroxetyl ethylenediamine salt
  • An imidazoline type amphoteric surfactant, an amino acid type surfactant such as ⁇ fatty acid acyl-L-alginate salt, etc. can be used alone or in combination as long as the effects of the present invention are not impaired.
  • the blending amount is preferably 0.01 to 5% of the entire composition.
  • Active ingredients other than isopropylmethylphenol and triclosan include anti-inflammatory agents such as tranexamic acid and epsilon monoaminocaproic acid, dextranase, amylase, protease, mutanase, lysozyme, lytic enzyme, ritechenzyme Enzymes such as sodium fluoride, sodium monofluorophosphate, stannous fluoride, aluminum chlorohydroxy allantoin, allantoin, azulene, lysozyme chloride, ascorbine Vitamin c such as acid, dihydrocholesterol, glycyrrhetin salts, glycyrrhetinic acid, hydrocholesterol, chlorophyll, copper chlorophyllin sodium, thyme, argon, tiyodi, hamamelis, etc.
  • anti-inflammatory agents such as tranexamic acid and epsilon monoaminocaproic acid, dextran
  • plant extracts copper dalconate, caropeptide, sodium polyphosphate Sulfur, water-soluble inorganic phosphate compound, polyvinyl pyrrolidone, anticalculus agent, anti-plaque agent, potassium nitrate, aluminum lactate and the like can be added.
  • the blending amount of these active ingredients can be an effective amount as long as the effects of the present invention are not hindered.
  • a water-soluble coloring matter having high safety such as Blue No. 1, Green No. 3, Yellow No. 4, Red No. 105 can be added.
  • PET polyethylene terephthalate
  • glass polypropylene
  • polyethylene polyethylene
  • liquid oral compositions Preparation of these liquid oral compositions includes isopropylmethylphenol (Osaka Kasei), sodium lauryl sulfate (Toho Chemical Industries), myristyl sulfate (Nikko Chemicals), cetyl sulfate (Nikko Chemicals).
  • Lauroyl sarcosine sodium (manufactured by Kawaken Fine Chemical Co., Ltd.), myristoyl sarcosine sodium (manufactured by Nikko Chemicals), palmitoyl sarcosine sodium (manufactured by Nikko Chemicals), polyoxyethylene (40) hydrogenated castor oil (manufactured by Nikko Chemicals) , Polyoxyethylene (60) hydrogenated castor oil (Nikko Chemicals), polyoxyethylene (100) hydrogenated castor oil (Nikko Chemicals), polyoxyethylene (40) stearyl ether (Nihon Emulsion), polyoxyethylene Tylene (40) (Made by Nippon Emulsion), polyoxyethylene (20) cetyl ether (made by Nippon Emulsion), polyoxyethylene (10) cetyl ether (made by Nikko Chemicals), glycerin (85%, made by Sakamoto Pharmaceutical Co., Ltd.) , Propylene glycol (manufactured
  • a model biofilm carrier prepared by treating a hydroxyapatite (HA) plate (made by Asahi Optical Co., Ltd.) (diameter 7mm x thickness 3.5mm) with human unstimulated saliva filtered through a 0.45 / im filter for 4 hours. Used for.
  • the culture solution was prepared by adding 5 mg of hemin (manufactured by Sigma) and 0.5 mg of menadione (manufactured by Sigma) to a solution obtained by dissolving 30 g of trypticase soy broth (manufactured by Difco) in 1 L of purified water.
  • Streptococcus gordonii ATC51656 and Actinomyces naeslandi ATCC51655 were used as oral resident bacteria, and Borfiromonas gingivalis ATCC 33277 was used as a pathogenic bacterium.
  • These 3 bacterial species were inoculated into the above culture solution to 2 x 10 7 cfu / mL (cfu: colony for mining units), respectively, and 37 ° C with saliva-treated HA carrier under anaerobic conditions (5% carbonic acid). Gas and 95% nitrogen) were continuously cultured for 2 weeks (the replacement rate of the culture medium was 10 Vol%) to form a model biofilm with a mixture of three bacterial species on the HA surface.
  • the formed model biofilm was immersed in 2 mL of the samples shown in Tables 1 to 3 for 3 minutes and washed 6 times with 1 mL of sterile physiological saline.
  • the model biofilm is then dispersed by sonication (200 ⁇ , 10 seconds) with 4 mL of sterile physiological saline, a tripty case soy agar plate (made by Dif co) containing 10% sheep defibrillating blood, and kanamycin sulfate (200 mg / L).
  • kanamycin sulfate 200 mg / L.
  • 50 ⁇ L of the triptycase soy blood agar plate was smeared and cultured under anaerobic conditions. The grown colonies were counted, and the number of remaining B. gingivalis bacteria (cfu) was determined and determined according to the following criteria.
  • Viable count is less than 10 6
  • Viable count is 10 6 or more and less than 10 7
  • Viable count is 10 7 or more and less than 10 8
  • the liquid oral composition having the composition shown in Table 6 was evaluated for the bactericidal effect against airborne bacteria by the following method. The results are shown in Table 6.
  • Bacterial solution used was 30ml Trypticase Soy Broth (Difco) dissolved in 1L of purified water as a culture solution, and Actinomyces naesrandi ATCC 51655 was used as an oral resident bacterium at 37 ° C, anaerobic It was prepared by adding physiological saline so that the permeability at 550 nm of the liquid cultured for 1 day under the conditions (5% carbon dioxide gas, 95% nitrogen) was 20. Samples shown in Table 5 2. Add 0.3 mL of bacterial solution to 7 mL, stir, react at 37 ° C for 1 minute, stir again, and then add a tube containing 2.7 mL of the culture solution in advance.
  • Viable count is less than 10 3
  • Viable count is 10 3 or more and less than 10 4
  • Titanic acid 0.05 0.05 0.05 0.05 0.05 Sodium titer 0.3 0.3 0.3 0.3 0.3 0.3 Purified water residue Residue residue Residual total 100 100 100 100 100 100 100 Total water content 99.2 95.2 83.5 62.2 83.5 Periodontal pathogenicity ', "
  • liquid oral compositions of the following examples were prepared by conventional methods and evaluated in the same manner as described above. It had floating fungicidal ability (evaluated only in Examples 22 and 23 having a composition containing triclosan), appearance stability, and feeling of use.
  • flavor of the composition shown in following Table 7 was used for the fragrance

Abstract

Composition orale liquide contenant de l'isopropylméthylphénol, laquelle comprend : (A) un tensioactif anionique sélectionné parmi un alkylsulfate de sodium et une N-acylsarcosine sodique ; (B) un tensioactif non ionique sélectionné parmi une huile de ricin hydrogénée polyoxyéthylénique ayant un nombre molaire moyen d'unités oxyde d'éthylène ajoutées de 40 à 100 moles et un éther d'alkyle et de polyoxyde d'éthylène ayant 16 à 18 atomes de carbone dans la chaîne carbonée et ayant un nombre molaire moyen d'unités oxyde d'éthylène ajoutées de 10 à 40 moles ; et (C) un agent mouillant sélectionné parmi la glycérine, le propylèneglycol, le butylèneglycol et un polyéthylèneglycol ayant un poids moléculaire moyen de 190 à 630 en quantité de 5 à 15 % en masse par rapport à la quantité totale de la composition, laquelle a une teneur en humidité supérieure ou égale à 70 % en masse et laquelle ne contient pratiquement pas d'éthanol. Il devient possible de produire une composition orale liquide présentant un effet de perméation/bactéricide élevé contre un biofilm parodontopathique, une bonne stabilité de l'aspect, une sensation collante réduite dans la cavité orale au cours de l'utilisation et après celle-ci et une faible irritation.
PCT/JP2007/061701 2006-06-23 2007-06-11 Composition orale liquide contenant de l'isopropylméthylphénol WO2007148551A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2008522389A JP5136797B2 (ja) 2006-06-23 2007-06-11 イソプロピルメチルフェノール含有液体口腔用組成物
KR1020087028642A KR101380508B1 (ko) 2006-06-23 2007-06-11 이소프로필메틸페놀 함유 액체 구강용 조성물

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2006-173710 2006-06-23
JP2006173710 2006-06-23

Publications (1)

Publication Number Publication Date
WO2007148551A1 true WO2007148551A1 (fr) 2007-12-27

Family

ID=38833292

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2007/061701 WO2007148551A1 (fr) 2006-06-23 2007-06-11 Composition orale liquide contenant de l'isopropylméthylphénol

Country Status (3)

Country Link
JP (1) JP5136797B2 (fr)
KR (1) KR101380508B1 (fr)
WO (1) WO2007148551A1 (fr)

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008110999A (ja) * 2008-02-04 2008-05-15 Mandom Corp 抗菌性組成物及びデオドラント剤
JP2010143889A (ja) * 2008-12-22 2010-07-01 Lion Corp 液体口腔用組成物
JP2010215558A (ja) * 2009-03-17 2010-09-30 Lion Corp 歯の脱灰抑制剤及び口腔用組成物
WO2011055708A1 (fr) * 2009-11-06 2011-05-12 ライオン株式会社 Composition liquide contenant de l'isopropyl méthyl phénol pour la cavité buccale
WO2011055707A1 (fr) * 2009-11-06 2011-05-12 ライオン株式会社 Composition de dentifrice
WO2011055706A1 (fr) * 2009-11-06 2011-05-12 ライオン株式会社 Composition de dentifrice
WO2011077847A1 (fr) * 2009-12-22 2011-06-30 ライオン株式会社 Composition liquide de type émulsion pour la cavité orale, et procédé de production de celle-ci
WO2011115034A1 (fr) * 2010-03-19 2011-09-22 ライオン株式会社 Composition orale liquide et méthode de production de ladite composition
US20120034312A1 (en) * 2009-04-03 2012-02-09 Glaxo Group Limited 4-isopropyl-3-methylphenol for the treatment of inflammation
JP2012126758A (ja) * 2010-12-13 2012-07-05 Kao Corp バイオフィルム除去剤
JP2013121954A (ja) * 2011-11-08 2013-06-20 Earth Chemical Co Ltd 歯肉のコラーゲン密度増強剤、歯肉のコラーゲン密度増強組成物および歯肉のコラーゲン密度の増強方法
JP2013245164A (ja) * 2012-05-23 2013-12-09 Kao Corp オートインデューサー−２阻害剤
JP2016056200A (ja) * 2012-12-21 2016-04-21 花王株式会社 抗菌剤組成物の製造方法
JP2018002719A (ja) * 2016-06-27 2018-01-11 サンスター株式会社 口腔用組成物
JP2019048801A (ja) * 2017-09-11 2019-03-28 ライオン株式会社 液体口腔用組成物
WO2019230707A1 (fr) * 2018-05-29 2019-12-05 ライオン株式会社 Composition pour la cavité buccale
JP2020002131A (ja) * 2018-06-25 2020-01-09 ロート製薬株式会社 液体口腔用組成物

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101932567B1 (ko) * 2015-11-04 2018-12-26 주식회사 엘지생활건강 바이오필름 제거용 조성물

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08325126A (ja) * 1995-05-26 1996-12-10 Kao Corp 口腔用組成物
JPH11322554A (ja) * 1998-05-06 1999-11-24 Sunstar Inc 口腔用組成物
JP2005179231A (ja) * 2003-12-18 2005-07-07 Lion Corp 液体口腔用組成物
JP2006069909A (ja) * 2004-08-31 2006-03-16 Lion Corp 歯磨組成物
JP2006124315A (ja) * 2004-10-28 2006-05-18 Lion Corp 口腔用組成物
JP2006182663A (ja) * 2004-12-27 2006-07-13 Lion Corp 液体口腔用組成物
JP2007106728A (ja) * 2005-10-17 2007-04-26 Lion Corp エタノール無配合液体口腔用組成物

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08325126A (ja) * 1995-05-26 1996-12-10 Kao Corp 口腔用組成物
JPH11322554A (ja) * 1998-05-06 1999-11-24 Sunstar Inc 口腔用組成物
JP2005179231A (ja) * 2003-12-18 2005-07-07 Lion Corp 液体口腔用組成物
JP2006069909A (ja) * 2004-08-31 2006-03-16 Lion Corp 歯磨組成物
JP2006124315A (ja) * 2004-10-28 2006-05-18 Lion Corp 口腔用組成物
JP2006182663A (ja) * 2004-12-27 2006-07-13 Lion Corp 液体口腔用組成物
JP2007106728A (ja) * 2005-10-17 2007-04-26 Lion Corp エタノール無配合液体口腔用組成物

Cited By (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008110999A (ja) * 2008-02-04 2008-05-15 Mandom Corp 抗菌性組成物及びデオドラント剤
JP2010143889A (ja) * 2008-12-22 2010-07-01 Lion Corp 液体口腔用組成物
JP2010215558A (ja) * 2009-03-17 2010-09-30 Lion Corp 歯の脱灰抑制剤及び口腔用組成物
US20120034312A1 (en) * 2009-04-03 2012-02-09 Glaxo Group Limited 4-isopropyl-3-methylphenol for the treatment of inflammation
JP2011098917A (ja) * 2009-11-06 2011-05-19 Lion Corp 歯磨剤組成物
WO2011055706A1 (fr) * 2009-11-06 2011-05-12 ライオン株式会社 Composition de dentifrice
WO2011055707A1 (fr) * 2009-11-06 2011-05-12 ライオン株式会社 Composition de dentifrice
JP2011098918A (ja) * 2009-11-06 2011-05-19 Lion Corp 歯磨剤組成物
WO2011055708A1 (fr) * 2009-11-06 2011-05-12 ライオン株式会社 Composition liquide contenant de l'isopropyl méthyl phénol pour la cavité buccale
CN102573769B (zh) * 2009-11-06 2013-12-04 狮王株式会社 洁齿剂组合物
CN102573769A (zh) * 2009-11-06 2012-07-11 狮王株式会社 洁齿剂组合物
WO2011077847A1 (fr) * 2009-12-22 2011-06-30 ライオン株式会社 Composition liquide de type émulsion pour la cavité orale, et procédé de production de celle-ci
JP5690744B2 (ja) * 2009-12-22 2015-03-25 ライオン株式会社 乳化型液体口腔用組成物及びその製造方法
CN102655844A (zh) * 2009-12-22 2012-09-05 狮王株式会社 乳化型液体口腔用组合物及其制造方法
CN102811702A (zh) * 2010-03-19 2012-12-05 狮王株式会社 液体口腔用组合物及其制造方法
WO2011115034A1 (fr) * 2010-03-19 2011-09-22 ライオン株式会社 Composition orale liquide et méthode de production de ladite composition
JP5690811B2 (ja) * 2010-03-19 2015-03-25 ライオン株式会社 液体口腔用組成物及びその製造方法
JP2012126758A (ja) * 2010-12-13 2012-07-05 Kao Corp バイオフィルム除去剤
JP2013121954A (ja) * 2011-11-08 2013-06-20 Earth Chemical Co Ltd 歯肉のコラーゲン密度増強剤、歯肉のコラーゲン密度増強組成物および歯肉のコラーゲン密度の増強方法
JP2013245164A (ja) * 2012-05-23 2013-12-09 Kao Corp オートインデューサー−２阻害剤
JP2016056200A (ja) * 2012-12-21 2016-04-21 花王株式会社 抗菌剤組成物の製造方法
JP2018002719A (ja) * 2016-06-27 2018-01-11 サンスター株式会社 口腔用組成物
JP2019048801A (ja) * 2017-09-11 2019-03-28 ライオン株式会社 液体口腔用組成物
WO2019230707A1 (fr) * 2018-05-29 2019-12-05 ライオン株式会社 Composition pour la cavité buccale
CN111867550A (zh) * 2018-05-29 2020-10-30 狮王株式会社 口腔用组合物
CN111867550B (zh) * 2018-05-29 2023-04-14 狮王株式会社 口腔用组合物
JP2020002131A (ja) * 2018-06-25 2020-01-09 ロート製薬株式会社 液体口腔用組成物
JP7403977B2 (ja) 2018-06-25 2023-12-25 ロート製薬株式会社 液体口腔用組成物

Also Published As

Publication number Publication date
JP5136797B2 (ja) 2013-02-06
KR20090023577A (ko) 2009-03-05
KR101380508B1 (ko) 2014-04-01
JPWO2007148551A1 (ja) 2009-11-19

Similar Documents

Publication Publication Date Title
WO2007148551A1 (fr) Composition orale liquide contenant de l'isopropylméthylphénol
JP4591680B2 (ja) 液体口腔用組成物
JP4957882B2 (ja) エタノール無配合洗口剤組成物
JP5526619B2 (ja) 練歯磨剤組成物
JP5470837B2 (ja) 液体口腔用組成物
WO2010143589A1 (fr) Composition pour la cavité buccale
JP5729252B2 (ja) 口腔用組成物
JP5359546B2 (ja) 液体口腔用組成物
JP5310553B2 (ja) 液体口腔用組成物、及びカチオン性殺菌剤の殺菌力向上方法
JP2009256228A (ja) 液体口腔用組成物
JP4873154B2 (ja) 液体口腔用組成物
JP2007031394A (ja) 液体口腔用組成物及びｌ−メントールの析出防止方法
JP5853387B2 (ja) 液体口腔用組成物及び該組成物へ成分を安定化配合する方法
JP5682283B2 (ja) 液体口腔用組成物
JP2010143843A (ja) 液体口腔用組成物
CN107205899B (zh) 液体口腔用组合物
JP2009096748A (ja) 液体口腔用組成物
JP4952940B2 (ja) 液体口腔用組成物
JP5051347B2 (ja) 液体口腔用組成物
JP2011126819A (ja) 口腔用組成物
JP2005187333A (ja) う蝕予防用塗布剤組成物
JP4284522B2 (ja) 練歯磨組成物
CN109689016B (zh) 液体口腔用组合物
KR101773227B1 (ko) 치마제 조성물
WO2023100804A1 (fr) Composition liquide à usage oral

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07744993

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2008522389

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 1020087028642

Country of ref document: KR

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07744993

Country of ref document: EP

Kind code of ref document: A1